We are live on ! Find out more
LVTX

LAVA Therapeutics
LVTX

Delisted

LVTX was delisted on the 20th of November, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in LAVA Therapeutics in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

39.25% less ownership

Funds ownership: 39.25% → 0% (-39%)

100% less funds holding

Funds holding: 21 → 0 (-21)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $16.1M → $0 (-$16.1M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 21

Holders
–
Holders Change
-21
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SC
Shay Capital
New York
-$3.98M
2
RG
Redmile Group
California
-$3.24M
3
BCM
BML Capital Management
Indiana
-$3.07M
4
S
Sanofi
France
-$2.99M
5
MC
Merck & Co
New Jersey
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
1
Shay Capital
New York
– -$3.98M -2,548,730 Closed
RG
2
Redmile Group
California
– -$3.24M -2,074,372 Closed
BCM
3
BML Capital Management
Indiana
– -$3.07M -1,970,610 Closed
S
4
Sanofi
France
– -$2.99M -1,919,455 Closed
MC
5
Merck & Co
New Jersey
– -$1.79M -1,149,345 Closed
GS
6
GTS Securities
New York
– -$312K -200,000 Closed
RC
7
Rangeley Capital
Connecticut
– -$257K -165,000 Closed
PNC Financial Services Group
8
PNC Financial Services Group
Pennsylvania
– -$101K -65,000 Closed
Citadel Advisors
9
Citadel Advisors
Florida
– -$83.2K -53,308 Closed
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
– -$69K -44,348 Closed
LDNAM
11
Lepercq De Neuflize Asset Management
New York
– -$48.4K -31,000 Closed
JC
12
JBF Capital
Colorado
– -$37.3K -23,911 Closed
XT
13
XTX Topco
Cayman Islands
– -$33.9K -21,727 Closed
UBS Group
14
UBS Group
Switzerland
– -$24.8K -15,871 Closed
TC
15
Torno Capital
Massachusetts
– -$23.4K -15,000 Closed
Geode Capital Management
16
Geode Capital Management
Massachusetts
– -$22.1K -14,170 Closed
EPM
17
Equitec Proprietary Markets
Illinois
– -$19.5K -12,500 Closed
Jones Financial Companies
18
Jones Financial Companies
Missouri
– -$636 -400 Closed
TFGT
19
TS Financial Group (TSFG)
Illinois
– -$1K -400 Closed
SS
20
SBI Securities
Japan
– -$468 -300 Closed
SWIM
21
Smallwood Wealth Investment Management
New Jersey
– -$40 -26 Closed

LVTX Hedge Fund Activity: Q4 2025 in Review

0 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q4 2025, worth a combined $0 — down 100% from $16.1M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of LVTX and 0 opened new positions — a net loss of 21 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Shay Capital, exiting entirely with an estimated $3.98M sold.

  • 0 institutional investors held LAVA Therapeutics (LVTX) as of Q4 2025, down from 21 in Q3 2025.
  • Funds reported $0 of LAVA Therapeutics stock for Q4 2025, down 100% quarter-over-quarter.
  • 0 funds opened new LAVA Therapeutics positions in Q4 2025 and 21 closed out, a net change of -21 holders.
  • The largest LAVA Therapeutics seller in Q4 2025 was Shay Capital, an estimated $3.98M sold.

Based on aggregated 13F filings for Q4 2025.